X. Tong

发表

[Study on genotypic resistance mutations to antiretroviral drugs on HIV strains of treated and treatment-naive HIV-1 infectious patients in Hubei province].

Xiao-qiong Wang, X. Tong, Heng Tang, 2007, Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi.

PTC725, an NS4B-Targeting Compound, Inhibits a Hepatitis C Virus Genotype 3 Replicon, as Predicted by Genome Sequence Analysis and Determined Experimentally

X. Tong, Z. Gu, F. Lahser, 2016, Antimicrobial Agents and Chemotherapy.

Identification of PTC725, an Orally Bioavailable Small Molecule That Selectively Targets the Hepatitis C Virus NS4B Protein

S. Peltz, X. Tong, Z. Gu, 2013, Antimicrobial Agents and Chemotherapy.

Identification of HCV protease inhibitor resistance mutations by selection pressure-based method

X. Tong, P. Qiu, J. Greene, 2009, Nucleic acids research.

Novel substituted pyrimidines as HCV replication (replicase) inhibitors.

X. Tong, R. Reynolds, B. Feld, 2012, Bioorganic & Medicinal Chemistry Letters.

Pyridofuran substituted pyrimidine derivatives as HCV replication (replicase) inhibitors.

X. Tong, M. Maccoss, R. Reynolds, 2012, Bioorganic & medicinal chemistry letters.

5-Benzothiazole substituted pyrimidine derivatives as HCV replication (replicase) inhibitors.

X. Tong, M. Maccoss, R. Reynolds, 2012, Bioorganic & medicinal chemistry letters.

In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir.

S. So, X. Tong, Lewyn Li, 2014, The Journal of infectious diseases.

A novel HCV NS3 protease mutation selected by combination treatment of the protease inhibitor boceprevir and NS5B polymerase inhibitors.

X. Tong, H. Huang, E. Xia, 2009, Antiviral research.

Identification of the NS5B S282T Resistant Variant and Two Novel Amino Acid Substitutions That Affect Replication Capacity in Hepatitis C Virus-Infected Patients Treated with Mericitabine and Danoprevir

X. Tong, Lewyn Li, I. Nájera, 2014, Antimicrobial Agents and Chemotherapy.

Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients

X. Tong, R. D. de Knegt, H. Janssen, 2010, Hepatology.

Novel protease and polymerase inhibiting agents to treat chronic hepatitis C infection

Tara L. Kieffer, A. Kwong, M. Tausek, 2008 .

Barrier to resistance: lessons from 2 direct-acting hepatitis C virus inhibitors, MK-5172 and Sofosbuvir.

A. Kwong, X. Tong, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Mericitabine and ritonavir‐boosted danoprevir with or without ribavirin in treatment‐naive HCV genotype 1 patients: INFORM‐SVR study

P. Marcellin, X. Tong, S. Zeuzem, 2015, Liver international : official journal of the International Association for the Study of the Liver.

P4 capped amides and lactams as HCV NS3 protease inhibitors with improved potency and DMPK profile.

X. Tong, A. Prongay, V. Girijavallabhan, 2010, Bioorganic & medicinal chemistry letters.

Towards the second generation of Boceprevir: Dithianes as an alternative P2 substituent for 2,2-dimethyl cycloproyl proline in HCV NS3 protease inhibitors.

X. Tong, R. Doll, Zhuyan Guo, 2010, Bioorganic & medicinal chemistry letters.

Novel potent inhibitors of hepatitis C virus (HCV) NS3 protease with cyclic sulfonyl P3 cappings.

X. Tong, F. G. Njoroge, K. Cheng, 2009, Bioorganic & medicinal chemistry letters.

Characterization of resistance mutations against HCV ketoamide protease inhibitors.

X. Tong, R. Ralston, Zhuyan Guo, 2008, Antiviral research.

Merimepodib, an IMPDH inhibitor, suppresses replication of Zika virus and other emerging viral pathogens

A. Kwong, X. Tong, T. Koma, 2018, Antiviral research.

Preclinical Characterization of the Antiviral Activity of SCH 900518 (Narlaprevir), a Novel Mechanism-Based Inhibitor of Hepatitis C Virus NS3 Protease

X. Tong, R. Ralston, B. Feld, 2010, Antimicrobial Agents and Chemotherapy.

Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa‐2b

X. Tong, R. Ralston, S. Zeuzem, 2012, Journal of viral hepatitis.

Cyclic sulfones as novel P3-caps for hepatitis C virus NS3/4A (HCV NS3/4A) protease inhibitors: synthesis and evaluation of inhibitors with improved potency and pharmacokinetic profiles.

X. Tong, A. McPhail, A. Arasappan, 2010, Journal of medicinal chemistry.

1412 INTERFERON-FREE TREATMENT WITH A COMBINATION OF MERICITABINE AND DANOPREVIR/R WITH OR WITHOUT RIBAVIRIN IN TREATMENT-NAIVE HCV GENOTYPE 1-INFECTED PATIENTS

P. Marcellin, X. Tong, S. Zeuzem, 2012 .

[432] FAVORABLE CROSS-RESISTANCE PROFILE OF TWO NOVEL HEPATITIS C VIRUS INHIBITORS, SCH-503034 AND HCV-796, AND ENHANCED ANTI-REPLICON ACTIVITY MEDIATED BY THE COMBINED USE OF BOTH COMPOUNDS

X. Tong, E. Emini, R. Ralston, 2007 .

Mutations Conferring Resistance to SCH6, a Novel Hepatitis C Virus NS3/4A Protease Inhibitor

S. Lemon, X. Tong, N. Bourne, 2006, Journal of Biological Chemistry.

Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus–infected patients

F. S. Domingues, X. Tong, R. Ralston, 2009, Hepatology.

SCH 503034, a Mechanism-Based Inhibitor of Hepatitis C Virus NS3 Protease, Suppresses Polyprotein Maturation and Enhances the Antiviral Activity of Alpha Interferon in Replicon Cells

N. Butkiewicz, F. Gheyas, X. Tong, 2006, Antimicrobial Agents and Chemotherapy.

Molecular epidemiology of human immunodeficiency virus type 1 and hepatitis C virus in former blood donors in central China.

Xiao-qiong Wang, X. Tong, Heng Tang, 2008, AIDS research and human retroviruses.

The introduction of P4 substituted 1-methylcyclohexyl groups into Boceprevir: a change in direction in the search for a second generation HCV NS3 protease inhibitor.

Zhuyan Guo, Frank Bennett, X. Tong, 2010, Bioorganic & medicinal chemistry letters.

Amino acid mutations of the infectious clone from Chinese EIAV attenuated vaccine resulted in reversion of virulence.

X. Tong, Xiang He, Y. Shao, 2006, Vaccine.

Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034.

X. Tong, B. Malcolm, A. Skelton, 2006, Antiviral research.

Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies.

D. Hazuda, J. Albrecht, X. Tong, 2013, Virology.

65 CLONAL ANALYSIS OF MUTATIONS SELECTED IN THE HCV NS3 PROTEASE DOMAIN OF GENOTYPE 1 NON-RESPONDERS TREATED WITH BOCEPREVIR (SCH503034)

X. Tong, R. Ralston, S. Zeuzem, 2008 .

Discovery of novel P3 sulfonamide-capped inhibitors of HCV NS3 protease. Inhibitors with improved cellular potencies.

X. Tong, A. Arasappan, K. Cheng, 2009, Bioorganic & medicinal chemistry.

Trans-complementation of HCV replication by non-structural protein 5A.

X. Tong, B. Malcolm, 2006, Virus research.

Analysis of HCV resistance mutations during combination therapy with protease inhibitor boceprevir and PEG-IFN alpha-2b using TaqMan mismatch amplification mutation assay.

X. Tong, P. Qiu, S. Curry, 2008, Journal of virological methods.

Impact of naturally occurring variants of HCV protease on the binding of different classes of protease inhibitors.

X. Tong, P. Qiu, Zhuyan Guo, 2006, Biochemistry.

Computational Study of the Effects of Mutations A156T, D168V, and D168Q on the Binding of HCV Protease Inhibitors.

X. Tong, T. Fischmann, Zhuyan Guo, 2006, Journal of chemical theory and computation.

Discovery of Narlaprevir (SCH 900518): A Potent, Second Generation HCV NS3 Serine Protease Inhibitor.

Weiying Yang, Frank Bennett, Jesse Wong, 2010, ACS medicinal chemistry letters.

Frequencies of Resistance-Associated Amino Acid Variants Following Combination Treatment with Boceprevir Plus PEGINTRON (PegInterferon Alfa-2b)/Ribavir in in Patients With Chronic Hepatitis C (CHC), Genotype 1 (G1)

E. Schiff, J. Albrecht, X. Tong, 2010 .

Outcomes and Susceptibility to Neuraminidase Inhibitors in Individuals Infected With Different Influenza B Lineages: The Influenza Resistance Information Study.

B. Cowling, X. Tong, C. Boucher, 2016, The Journal of infectious diseases.

Second-generation highly potent and selective inhibitors of the hepatitis C virus NS3 serine protease.

Weiying Yang, Frank Bennett, X. Tong, 2009, Journal of medicinal chemistry.

Correlation between PAMPA permeability and cellular activities of hepatitis C virus protease inhibitors.

Robert Chase, Sony Agrawal, X. Tong, 2008, Biochemical pharmacology.

Combined amino acid mutations occurring in the envelope closely correlate with pathogenicity of EIAV

X. Tong, Xiang He, Y. Shao, 2006, Archives of Virology.

Toward the back-up of boceprevir (SCH 503034): discovery of new extended P4-capped ketoamide inhibitors of hepatitis C virus NS3 serine protease with improved potency and pharmacokinetic profiles.

Zhuyan Guo, Frank Bennett, Sumei Ruan, 2009, Journal of medicinal chemistry.

Toward second generation hepatitis C virus NS3 serine protease inhibitors: discovery of novel P4 modified analogues with improved potency and pharmacokinetic profile.

Frank Bennett, X. Tong, A. Arasappan, 2009, Journal of medicinal chemistry.

Synthesis and SAR of geminal substitutions at the C5' carbosugar position of pyrimidine-derived HCV inhibitors.

X. Tong, M. Maccoss, N. Bansal, 2012, Bioorganic & medicinal chemistry letters.

Synthesis and SAR of pyridothiazole substituted pyrimidine derived HCV replication inhibitors.

X. Tong, M. Maccoss, N. Bansal, 2012, Bioorganic & medicinal chemistry letters.

Interferon in Replicon Cells Enhances the Antiviral Activity of Alpha Suppresses Polyprotein Maturation and of Hepatitis C Virus NS 3 Protease , SCH 503034 , a Mechanism-Based Inhibitor

F. Gheyas, X. Tong, C. Jiang, 2005 .

Discovery and structure-activity relationship of P1-P3 ketoamide derived macrocyclic inhibitors of hepatitis C virus NS3 protease.

Andrea Hart, Robert Chase, Sony Agrawal, 2009, Journal of medicinal chemistry.

A conservative domain shared by HIV gp120 and EIAV gp90: implications for HIV vaccine design.

X. Tong, Y. Shao, Xiujuan Fan, 2005, AIDS research and human retroviruses.

A conserved structural motif shared by EIAV gp90 and HIV gp120

X. Tong, Y. Shao, Xiao-yan Zhang, 2005 .

Design, synthesis, and evaluation of oxygen-containing macrocyclic peptidomimetics as inhibitors of HCV NS3 protease.

X. Tong, Melissa L. Blackman, J. Pichardo, 2009, Journal of medicinal chemistry.